Successful treatment of high-risk myelodysplastic syndrome with decitabine-based chemotherapy followed by haploidentical lymphocyte infusion: A case report and literature review

RATIONALE: The current therapy for elderly patients with high-risk myelodysplastic syndromes (MDSs) remains unsatisfactory. Decitabine, which has been approved to treat MDS, cannot eliminate malignant clones of MDS. PATIENT CONCERNS: A 68-year-old woman presented with multiple divergent bleeding poi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yuanyuan, Shen, Jianliang, Wang, Li-Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916686/
https://www.ncbi.nlm.nih.gov/pubmed/29668607
http://dx.doi.org/10.1097/MD.0000000000010434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916686/
https://www.ncbi.nlm.nih.gov/pubmed/29668607
http://dx.doi.org/10.1097/MD.0000000000010434

Ejemplares similares